Henry Ford Health System Signs Development and Commercialization Agreement with G3 Pharma for its Galectin-3 inhibitors
Shots:
- Henry to get an exclusive option to license US patent application 14/654-140 for Galectin-3 inhibitors and will acquire minority equity in G3 Pharmaceuticals
- The focus of the agreement is to advance therapies for heart failure with preserved ejection fraction (HFpEF) without no approved treatments
- Galectin-3 is a protein for oral use and is indicated for the treatment of diastolic heart failure also known as HFpEF
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
